首页> 外文期刊>Assay and drug development technologies >Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay.
【24h】

Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay.

机译:临床前筛查抗银屑病药物的一系列抗增殖检测方法的评估:比色和荧光检测方法与胸苷掺入检测方法的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

Established treatments for psoriasis are generally based on antiproliferative, anti-inflammatory, or differentiation-modifying activity, or a combination of these effects. New agents for the treatment of psoriasis could be identified by high-throughput screening (HTS) of large compound libraries using keratinocyte proliferation models. Although several new proliferation assays have been developed, the radioactive [(3)H]-thymidine incorporation assay is still considered to be the gold standard for the evaluation of keratinocyte proliferation in vitro. In this study, we compare a number of simple, and reliable, colorimetric (MTT, NRU, SRB, and CVS), and fluorimetric (CAM and AB) methods with the [(3)H]-thymidine incorporation assay for the measurement of keratinocyte proliferation in the exponential growth phase in 96-well formats. The concentrations that induced 50% growth inhibition (GI(50)) were determined by each assay for the established antipsoriatics, dithranol, and methotrexate. Strong correlations were observed between the percentage growth inhibitions determined by the radioactive and the colorimetric assays, with no significant differences (P > 0.05) between their GI(50) values. The colorimetric assays are thus suitable alternatives to the radioactive assay for quantifying keratinocyte growth inhibition. We have also validated the use of the HaCaT cell line as a representative of the hyperproliferative psoriatic epidermis, in the preclinical screening of experimental anti-psoriatic agents.
机译:牛皮癣的既定治疗方法通常基于抗增殖,抗炎或分化调节活性或这些作用的组合。可以通过使用角质形成细胞增殖模型对大型化合物库进行高通量筛选(HTS)来鉴定治疗牛皮癣的新药物。尽管已经开发了几种新的增殖测定法,但放射性[(3)H]-胸苷掺入测定法仍被认为是体外评价角质形成细胞增殖的金标准。在这项研究中,我们比较了几种简单可靠的比色法(MTT,NRU,SRB和CVS)和荧光法(CAM和AB)与[(3)H]-胸苷掺入法测定96孔格式的指数生长期中的角质形成细胞增殖。通过每种确定的抗银屑病药物,二乙醇胺和甲氨蝶呤的测定方法确定诱导50%生长抑制的浓度(GI(50))。放射性和比色法测定的生长抑制百分比之间观察到强烈的相关性,其GI(50)值之间无显着差异(P> 0.05)。因此,比色测定法是放射性测定法的合适替代方法,用于定量角质形成细胞的生长抑制。在实验性抗银屑病药物的临床前筛选中,我们还验证了HaCaT细胞系作为过度增殖性银屑病表皮的代表的用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号